Concomitancy and Indications for Idelalisib Use

Basic Details
Date Posted
Monday, March 12, 2018
Status
Complete
Medical Product
bendamustine
bortezomib
chlorambucil
cyclophosphamide
doxorubicin
ibritumomab
ibrutinib
idelalisib
lenalidomide
obinutuzumab
ofatumumab
prednisone
rituximab
vincristine
Description

This report contains estimated numbers of idelalisib users and idelalisib users with concomitant use of several anti-cancer agents as well as cancer diagnoses around the time of idelalisib use. Data from July 23, 2014 to December 31, 2015 from 15 health plans contributing to the Sentinel Distributed Database (SDD) were included in this report. This request was distributed on May 19, 2016.

Additional Details
FDA Center
CDER
Time Period
July 23, 2014 - December 31, 2015
Study Type
Modular Program
Assessment Type
Exploratory Analyses
Population / Cohort
Individuals 18 years of age and older
Data Sources
Sentinel Distributed Database (SDD)